Opinion|Videos|August 5, 2024
Key Takeaways on the Clinical Utility of ctDNA in Colorectal Cancer
Author(s)Stacey A. Cohen, MD, Daniel H. Ahn, DO
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, share their key takeaways on the clinical utility of ctDNA in the treatment of patients with colorectal cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
More than two-thirds of patients with mismatch repair–deficient locally advanced rectal cancer achieved a clinical complete response with dostarlimab alone.
Advertisement
Advertisement
Trending on CancerNetwork
1
KITE-753 Trials in R/R DLBCL Placed on Partial Clinical Hold for ICANS
2
Flood-Damaged Plant May Prolong US Chemotherapy Shortages to 2028
3
Managing FLOT Toxicity With Dose Reductions in Gastroesophageal Cancer
4
How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?
5